DE998300T1 - Zusammensetzungen zur modulation der empfänglichkeit für corticosteroiden - Google Patents
Zusammensetzungen zur modulation der empfänglichkeit für corticosteroidenInfo
- Publication number
- DE998300T1 DE998300T1 DE0998300T DE98912929T DE998300T1 DE 998300 T1 DE998300 T1 DE 998300T1 DE 0998300 T DE0998300 T DE 0998300T DE 98912929 T DE98912929 T DE 98912929T DE 998300 T1 DE998300 T1 DE 998300T1
- Authority
- DE
- Germany
- Prior art keywords
- patient
- corticosteroid
- agent
- disease
- suffers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003246 corticosteroid Substances 0.000 title claims 52
- 230000035945 sensitivity Effects 0.000 title claims 6
- 229960001334 corticosteroids Drugs 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 82
- 239000003795 chemical substances by application Substances 0.000 claims 34
- 150000003431 steroids Chemical class 0.000 claims 13
- 201000004624 Dermatitis Diseases 0.000 claims 12
- 102000013462 Interleukin-12 Human genes 0.000 claims 12
- 108010065805 Interleukin-12 Proteins 0.000 claims 12
- 229940117681 interleukin-12 Drugs 0.000 claims 12
- 230000004043 responsiveness Effects 0.000 claims 11
- 239000005557 antagonist Substances 0.000 claims 10
- 208000027866 inflammatory disease Diseases 0.000 claims 10
- 102100037850 Interferon gamma Human genes 0.000 claims 9
- 108010074328 Interferon-gamma Proteins 0.000 claims 9
- 208000011231 Crohn disease Diseases 0.000 claims 8
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 8
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 8
- 208000006673 asthma Diseases 0.000 claims 8
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 8
- 238000006243 chemical reaction Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 210000000822 natural killer cell Anatomy 0.000 claims 5
- 230000001739 rebound effect Effects 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 208000032467 Aplastic anaemia Diseases 0.000 claims 4
- 206010003399 Arthropod bite Diseases 0.000 claims 4
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 4
- 206010071155 Autoimmune arthritis Diseases 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 4
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 4
- 208000002691 Choroiditis Diseases 0.000 claims 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 4
- 206010010741 Conjunctivitis Diseases 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 208000005327 Diamond-Blackfan anemia 1 Diseases 0.000 claims 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 4
- 206010013774 Dry eye Diseases 0.000 claims 4
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 4
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 4
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 4
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 4
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 4
- 201000009906 Meningitis Diseases 0.000 claims 4
- 201000011152 Pemphigus Diseases 0.000 claims 4
- 206010065159 Polychondritis Diseases 0.000 claims 4
- 208000003971 Posterior uveitis Diseases 0.000 claims 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 4
- 206010036774 Proctitis Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 206010039710 Scleroderma Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 4
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 4
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 4
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 206010070517 Type 2 lepra reaction Diseases 0.000 claims 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
- 206010046914 Vaginal infection Diseases 0.000 claims 4
- 201000008100 Vaginitis Diseases 0.000 claims 4
- 230000001154 acute effect Effects 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 208000004631 alopecia areata Diseases 0.000 claims 4
- 208000002399 aphthous stomatitis Diseases 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 201000004982 autoimmune uveitis Diseases 0.000 claims 4
- 102000023732 binding proteins Human genes 0.000 claims 4
- 108091008324 binding proteins Proteins 0.000 claims 4
- 208000020670 canker sore Diseases 0.000 claims 4
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 4
- 208000037976 chronic inflammation Diseases 0.000 claims 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 4
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 201000004614 iritis Diseases 0.000 claims 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 4
- 206010023332 keratitis Diseases 0.000 claims 4
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 206010028417 myasthenia gravis Diseases 0.000 claims 4
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 4
- 230000036303 septic shock Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 4
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 3
- 102000011727 Caspases Human genes 0.000 claims 3
- 108010076667 Caspases Proteins 0.000 claims 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 3
- 101000828805 Cowpox virus (strain Brighton Red) Serine proteinase inhibitor 2 Proteins 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 229940092705 beclomethasone Drugs 0.000 claims 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 3
- 229960002537 betamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 3
- 244000309464 bull Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229960004544 cortisone Drugs 0.000 claims 3
- 229960001145 deflazacort Drugs 0.000 claims 3
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960000676 flunisolide Drugs 0.000 claims 3
- 229960000890 hydrocortisone Drugs 0.000 claims 3
- 229960003130 interferon gamma Drugs 0.000 claims 3
- 229960004584 methylprednisolone Drugs 0.000 claims 3
- 229960005205 prednisolone Drugs 0.000 claims 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 3
- 229960004618 prednisone Drugs 0.000 claims 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 3
- 229960005294 triamcinolone Drugs 0.000 claims 3
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 3
- 102000004560 Interleukin-12 Receptors Human genes 0.000 claims 2
- 108010017515 Interleukin-12 Receptors Proteins 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- 229940124748 beta 2 agonist Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 claims 1
- LITNEAPWQHVPOK-FFSVYQOJSA-N 2(1h)-pyrimidinone, 5-[3-[(1s,2s,4r)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro- Chemical compound C1=C(O[C@@H]2[C@H]3CC[C@H](C3)C2)C(OC)=CC=C1C1CNC(=O)NC1 LITNEAPWQHVPOK-FFSVYQOJSA-N 0.000 claims 1
- GNWCRBFQZDJFTI-UHFFFAOYSA-N 3-ethyl-1-(3-nitrophenyl)quinazoline-2,4-dione Chemical compound C12=CC=CC=C2C(=O)N(CC)C(=O)N1C1=CC=CC([N+]([O-])=O)=C1 GNWCRBFQZDJFTI-UHFFFAOYSA-N 0.000 claims 1
- PDUXMHXBBXXJFQ-UHFFFAOYSA-N 5,6-diethoxy-1-benzothiophene-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC2=C1SC(C(O)=O)=C2 PDUXMHXBBXXJFQ-UHFFFAOYSA-N 0.000 claims 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 1
- 102000004557 Interleukin-18 Receptors Human genes 0.000 claims 1
- 108010017537 Interleukin-18 Receptors Proteins 0.000 claims 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 claims 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 claims 1
- 239000002458 cell surface marker Substances 0.000 claims 1
- 229940095074 cyclic amp Drugs 0.000 claims 1
- 229950004687 denbufylline Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960001022 fenoterol Drugs 0.000 claims 1
- 230000000495 immunoinflammatory effect Effects 0.000 claims 1
- 229940039009 isoproterenol Drugs 0.000 claims 1
- 229950011565 nitraquazone Drugs 0.000 claims 1
- 150000008515 quinazolinediones Chemical class 0.000 claims 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims 1
- 229950005741 rolipram Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 229950009528 tibenelast Drugs 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
| US1634698A | 1998-01-30 | 1998-01-30 | |
| PCT/US1998/004916 WO1998041232A2 (en) | 1997-03-18 | 1998-03-12 | Compositions for modulating responsiveness to corticosteroids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE998300T1 true DE998300T1 (de) | 2001-03-01 |
Family
ID=26688484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE0998300T Pending DE998300T1 (de) | 1997-03-18 | 1998-03-12 | Zusammensetzungen zur modulation der empfänglichkeit für corticosteroiden |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0998300A1 (no) |
| JP (1) | JP2002504091A (no) |
| KR (1) | KR20000076420A (no) |
| CN (1) | CN1269722A (no) |
| AU (1) | AU734756B2 (no) |
| BG (1) | BG103808A (no) |
| BR (1) | BR9810409A (no) |
| CA (1) | CA2282845A1 (no) |
| DE (1) | DE998300T1 (no) |
| ES (1) | ES2146192T1 (no) |
| HU (1) | HUP0104439A3 (no) |
| ID (1) | ID22975A (no) |
| IL (1) | IL131815A0 (no) |
| NO (1) | NO994506L (no) |
| NZ (1) | NZ337769A (no) |
| PL (1) | PL336464A1 (no) |
| SI (1) | SI20110A (no) |
| SK (1) | SK122199A3 (no) |
| TR (1) | TR199902615T2 (no) |
| WO (1) | WO1998041232A2 (no) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
| US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| AR015966A1 (es) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| ATE274920T1 (de) * | 1997-10-31 | 2004-09-15 | Wyeth Corp | Verwendung von anti-il-12 antikörpern bei transplantationsabstossungen |
| EP1516630A3 (en) * | 1997-10-31 | 2006-05-03 | Wyeth | Use of anti-il-12 antibodies in transplantation rejection |
| WO1999025737A1 (en) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain |
| CA2323439A1 (en) * | 1998-03-16 | 1999-09-23 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
| EP1140206A4 (en) * | 1998-11-27 | 2002-04-10 | Technion Res & Dev Foundation | VACCINE BASED ON INTERFERON GAMMA INDUCTION FACTOR AND USE THEREOF FOR PROVIDING PROTECTION IMMUNITY AGAINST MULTIPLE SCLEROSIS |
| EP1137766B1 (en) * | 1998-12-09 | 2005-09-28 | Protein Design Labs, Inc. | Use of il-12 antibodies to treat psoriasis |
| JP2002539183A (ja) | 1999-03-16 | 2002-11-19 | サイトビア インコーポレイテッド | 置換２−アミノベンズアミドカスパーゼインヒビターおよびその使用 |
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| DE19915465A1 (de) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten |
| ATE363465T1 (de) | 1999-04-09 | 2007-06-15 | Cytovia Inc | Caspase inhibitoren und ihre verwendung |
| IL131047A0 (en) * | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
| DE60040397D1 (de) | 1999-08-27 | 2008-11-13 | Cytovia Inc | Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung |
| WO2001019373A2 (en) * | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| KR101111103B1 (ko) | 2000-02-10 | 2012-02-13 | 아보트 러보러터리즈 | 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법 |
| ATE332708T1 (de) * | 2000-06-06 | 2006-08-15 | Glaxo Group Ltd | Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält |
| AU7250301A (en) * | 2000-06-22 | 2002-01-02 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
| US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
| WO2002022127A1 (en) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
| EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| ME00549B (me) * | 2001-01-29 | 2011-10-10 | Serono Lab | Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja |
| US20030008822A1 (en) * | 2001-05-16 | 2003-01-09 | Charles Dinarello | Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| YU103003A (sh) | 2001-06-26 | 2006-05-25 | Abgenix Inc. | Antitela za opgl |
| EP1448205B1 (en) * | 2001-10-05 | 2011-03-23 | Zalicus Inc. | Combinations for the treatment of immunoinflammatory disorders |
| JP2003342196A (ja) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | 静脈注射用組成物、その製造法およびその製剤 |
| CA2509526A1 (en) * | 2002-09-24 | 2004-04-15 | Combinatorx, Incorporated | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| WO2004028545A1 (en) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| US20060083714A1 (en) * | 2003-01-27 | 2006-04-20 | Warner James M | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| WO2005110450A1 (ja) * | 2004-05-17 | 2005-11-24 | Keio University | 医薬組成物及び治療方法 |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| WO2006009114A1 (ja) * | 2004-07-16 | 2006-01-26 | Atsuo Sekiyama | Ｉｌ－１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物 |
| CA2584169A1 (en) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for chronic skin disease |
| ATE552032T1 (de) | 2005-07-14 | 2012-04-15 | Lithera Inc | Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe |
| AU2007313077B2 (en) * | 2006-10-17 | 2011-06-02 | Neothetics, Inc. | Methods, compositions, and formulations for the treatment of thyroid eye disease |
| NZ578065A (en) | 2007-01-16 | 2012-09-28 | Abbott Lab | Methods for treating psoriasis with an antibody which binds to an epitope |
| BRPI0809209A2 (pt) | 2007-03-29 | 2014-09-02 | Abbott Lab | Anticorpos il-12 anti-humanos cristalinos |
| KR20100126515A (ko) | 2008-03-18 | 2010-12-01 | 아보트 러보러터리즈 | 건선의 치료방법 |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| GB2485885B (en) | 2010-11-24 | 2015-06-17 | Neothetics Inc | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
| WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
| MX2023009352A (es) | 2021-02-10 | 2023-08-16 | Iolyx Therapeutics Inc | Metodos para la administracion oftalmica de roflumilast. |
| JP2024534570A (ja) * | 2021-09-22 | 2024-09-20 | イオリクス セラピューティクス，インコーポレーテッド | 眼炎症性疾患を処置する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
| ATE92762T1 (de) * | 1989-09-08 | 1993-08-15 | Glaxo Group Ltd | Medikamente. |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
| MX9304585A (es) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata. |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
| ATE258813T1 (de) * | 1995-04-14 | 2004-02-15 | Smithkline Beecham Corp | Vorrichtung zur dosierten inhalierung von beclomethason-diproprionat |
-
1998
- 1998-03-12 SK SK1221-99A patent/SK122199A3/sk unknown
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 CN CN98805124A patent/CN1269722A/zh active Pending
- 1998-03-12 SI SI9820032A patent/SI20110A/sl unknown
- 1998-03-12 DE DE0998300T patent/DE998300T1/de active Pending
- 1998-03-12 NZ NZ337769A patent/NZ337769A/xx unknown
- 1998-03-12 ES ES98912929T patent/ES2146192T1/es active Pending
- 1998-03-12 ID IDW991185A patent/ID22975A/id unknown
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/pt not_active IP Right Cessation
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/hu unknown
- 1998-03-12 EP EP98912929A patent/EP0998300A1/en not_active Withdrawn
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/en not_active Application Discontinuation
- 1998-03-12 CA CA002282845A patent/CA2282845A1/en not_active Abandoned
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/xx unknown
- 1998-03-12 JP JP54063398A patent/JP2002504091A/ja active Pending
- 1998-03-12 PL PL98336464A patent/PL336464A1/xx unknown
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/ko not_active Application Discontinuation
- 1998-03-12 IL IL13181598A patent/IL131815A0/xx unknown
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/no unknown
- 1999-10-13 BG BG103808A patent/BG103808A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU734756B2 (en) | 2001-06-21 |
| HUP0104439A2 (hu) | 2002-04-29 |
| SK122199A3 (en) | 2000-12-11 |
| WO1998041232A2 (en) | 1998-09-24 |
| AU6760498A (en) | 1998-10-12 |
| ES2146192T1 (es) | 2000-08-01 |
| CA2282845A1 (en) | 1998-09-24 |
| BR9810409A (pt) | 2000-08-22 |
| PL336464A1 (en) | 2000-06-19 |
| EP0998300A1 (en) | 2000-05-10 |
| NO994506L (no) | 1999-11-17 |
| IL131815A0 (en) | 2001-03-19 |
| CN1269722A (zh) | 2000-10-11 |
| TR199902615T2 (xx) | 2000-03-21 |
| BG103808A (en) | 2000-07-31 |
| JP2002504091A (ja) | 2002-02-05 |
| ID22975A (id) | 1999-12-23 |
| NZ337769A (en) | 2002-09-27 |
| SI20110A (sl) | 2000-06-30 |
| NO994506D0 (no) | 1999-09-17 |
| WO1998041232A3 (en) | 2000-10-05 |
| HUP0104439A3 (en) | 2002-08-28 |
| KR20000076420A (ko) | 2000-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE998300T1 (de) | Zusammensetzungen zur modulation der empfänglichkeit für corticosteroiden | |
| EP0975347B1 (de) | Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten | |
| DE60020269T2 (de) | Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs | |
| Jacobs et al. | Adrenal suppression following extradural steroids | |
| EP0804236B1 (de) | Verwendung von anti-tnf-antiköpern als arzneimittel zur behandlung von erkrankungen mit einem erhöhten interleukin-6 serumspiegel | |
| DE69233319T2 (de) | Aerosolzusammensetzungen für Arzneimittelsuspensionen | |
| DE69828155T2 (de) | Herstellung von pulveragglomeraten | |
| Ranke et al. | Long-term response to human growth hormone in 36 children with idiopathic growth hormone deficiency | |
| EP2266620A2 (de) | Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika | |
| DE4307508A1 (de) | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche) | |
| DE68908431T2 (de) | Methode zur Verminderung der Immunglobulin-E-Reaktion. | |
| Kim et al. | The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early puberty | |
| DE19541689A1 (de) | Kombinationsarzneimittel | |
| Cunningham et al. | Antiovulatory activity of synthetic corticoids | |
| DE69018799T2 (de) | IGF-I zur Behandlung von Nebeneffekten der Steroidtherapie. | |
| INGLE et al. | The relative potency of some adrenal cortical steroids in the muscle-work test | |
| Buskirk et al. | Treatment of multiple sclerosis with intrathecal steroids | |
| Domino et al. | Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose. | |
| Ichikawa et al. | Altered equilibrium between cortisol and cortisone in plasma in thyroid dysfunction and inflammatory diseases | |
| Schwarz | Idiopathic pulmonary fibrosis. | |
| EP1024831A2 (de) | Verwendung von tnf-antagonisten als arzneimittel zur behandlung von septischen erkrankungen | |
| Ladefoged et al. | Acetone-induced changes in the toxicokinetics of 2, 5-hexanedione in rabbits | |
| AONO et al. | Progesterone advancement of oestrogen-induced luteinizing hormone release during the mid-follicular phase in normal cyclic women | |
| WOOD et al. | Physiological Inhibition of Ovine Fetal Plasma Benin Activity by Cortisol | |
| EP1886694B1 (de) | Perorale Arzneiform mit Dienogest und Ethinylestradiol zur Kontrazeption |